BDX Intrinsic Value – BECTON DICKINSON & Reports Financial Results for Fourth Quarter of Fiscal Year 2023
November 24, 2023
🌥️Earnings Overview
On November 9, 2023, BECTON DICKINSON & ($NYSE:BDX) reported financial results for the fourth quarter of fiscal year 2023 (ending September 30, 2023). Total revenue was USD 5087.0 million, showing a 6.8% increase compared to the same period in the previous fiscal year. Net income, however, decreased by 62.4%, amounting to USD 108.0 million.
Market Price
During the day, the stock opened at $237.2 and closed at $232.2, which is a drop of 9.3% from the previous closing price of $255.9. The company attributed the decrease in net income mostly to increased operational expenses and higher interest expenses. Becton Dickinson & also stated that it is well-positioned to continue to generate strong cash flow and return value to shareholders. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for BDX. More…
| Total Revenues | Net Income | Net Margin |
| 19.37k | 1.42k | 9.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for BDX. More…
| Operations | Investing | Financing |
| 2.99k | -716 | -1.96k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for BDX. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 52.78k | 26.98k | 89.41 |
Key Ratios Snapshot
Some of the financial key ratios for BDX are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 4.2% | 10.6% | 10.9% |
| FCF Margin | ROE | ROA |
| 10.9% | 5.1% | 2.5% |
Analysis – BDX Intrinsic Value
At GoodWhale, we have analyzed the fundamentals of BECTON DICKINSON & Co. Our proprietary Valuation Line has determined that the fair value of BECTON DICKINSON & Co.’s share is around $264.9. However, the stock is currently trading at $232.2, which represents a discount of 12.4% from its fair value. This implies that investors can benefit from buying the stock at its current price, as it is undervalued. More…
Peers
Becton, Dickinson and Co is a medical technology company that manufactures and sells medical devices, instruments, and supplies. The company operates in three segments: BD Medical, BD Biosciences, and BD Diagnostics. It offers a wide range of products, including syringes, needles, catheters, blood collection devices, IV administration and infusion products, safety products, and sharps disposal systems. The company competes with Penumbra Inc, Teleflex Inc, SheerVision Inc, and other medical technology companies.
– Penumbra Inc ($NYSE:PEN)
Founded in 2002, Umbra is a leading global provider of shading and decorative products. The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods. Headquartered in Toronto, Canada, Umbra employs over 1,200 people worldwide.
Umbra’s market cap is 7.01B as of 2022. The company’s Return on Equity is -2.31%.
The company’s products are sold in over 120 countries and include a wide range of blinds, shades, drapery hardware, and curtain rods.
– Teleflex Inc ($NYSE:TFX)
Teleflex Incorporated is a diversified global provider of medical technologies designed to improve the health and quality of people’s lives. The Company provides solutions for critical care, anesthesia, surgical, urology and emergency medicine.
– SheerVision Inc ($OTCPK:SVSO)
SheerVision Inc is a US-based company that manufactures and sells ophthalmic surgical instruments and devices. The company has a market cap of 140.32k as of 2022 and a Return on Equity of -70.28%. SheerVision’s products are used by eye surgeons to correct vision problems such as nearsightedness, farsightedness, and astigmatism. The company’s products are sold through a network of distributors and retailers worldwide.
Summary
BECTON DICKINSON & Co. reported its financial results for the fourth quarter of fiscal year 2023 on November 9, 2023. Total revenue for the quarter was USD 5087.0 million, which represents a 6.8% year-over-year increase.
However, net income decreased 62.4% year-over-year to USD 108.0 million. As a result, the stock price dropped on the same day. Investors should evaluate this performance in context with the company’s long-term prospects and strategic plans for the future. They should also consider if current income and revenue trends are likely to continue. A thorough investing analysis should also include an assessment of competitive dynamics and potential risks to the company’s business model.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
